CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
靶向 CD19 的 CAR-T 细胞治疗对心脏内 B 细胞非霍奇金淋巴瘤安全有效
英文原题：CD19-targeting chimeric antigen receptor T-cell therapy is safe and effective for intra-cardiac B cell non-Hodgkin lymphoma.
查看英文原题
CD19-targeting chimeric antigen receptor T-cell therapy is safe and effective for intra-cardiac B cell non-Hodgkin lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
引言：CAR-T 细胞疗法治疗B细胞血液肿瘤高度有效，但由于潜在心脏毒性和假性进展，其在心腔内淋巴瘤中的安全性和疗效数据有限。 讨论：本文介绍4例高危病例的管理过程，采用了多学科方法，包括基线心脏风险评估、多模态心脏影像和血清心脏生物标志物监测、计划性重症监护支持，以及早期处理细胞因子释放综合征。 结论：CAR-T 疗法可有效、安全地治疗伴有心腔内病灶的B细胞血液系统恶性肿瘤。
展开英文摘要原文
INTRODUCTION: Chimeric antigen receptor T-cell (CAR-T) therapy is highly effective in B-cell blood cancers, but there is limited data on its safety and efficacy in intra-cardiac lymphoma, due to the potential risks of cardiotoxicity and pseudo-progression. DISCUSSION: We discuss four high-risk cases that were managed with a multi-disciplinary approach, including baseline cardiac risk assessment and surveillance with multimodal cardiac imaging and serum cardiac biomarkers, elective supportive care in the intensive care unit, and early treatment of cytokine release syndrome. CONCLUSION: CAR-T therapy can be effective and safe in the treatment of B-cell blood cancers with intra-cardiac disease.
论文信息
- 作者
- Chen DH、O'Reilly M、Cheok KP、Low R、Puranik R、Clark S、Walker JM、Manisty C
- 单位
- University College Hospital University College London Hospitals NHS Foundation Trust London UK.United Kingdom
- 期刊
- EJHaem2024 Dec
- 原文标识
- PubMed 39691274 · DOI 10.1002/jha2.1020
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →